ACTIVE

Railroad Therapeutics

Export PDF

Financial year 2025 · Closed on 31/12/2025

Net result-127,8 k €-58,1 %over 1 year
Gross margin-28,2 k €-138,3 %over 1 year
Equity437,8 k €+882,5 %over 1 year

Identity

Source · BCE/KBO

Railroad Therapeutics is a Private limited company incorporated in 2022. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Charleroi.

Legal situation
Normal situation
BCE/KBO no. / VAT
BE 0792.976.285
Incorporation
27/10/2022
Legal form
Private limited company
Registered office
Rue Clément Ader 10
6041 Charleroi · WallonieSee on map
Contributed capital
636 504,44 €
Latest accounts
31/12/2025
Signals
Solid equityLow riskGood liquidityPositive cashflowHealthy social debts

Financials

Source · NBB, 4 filings

Trend over 3 financial years

202520242023
Income statement
Gross margin-28,2 k €73,8 k €75,9 k €
EBITDA-91,1 k €12,9 k €20,9 k €
Operating result-230,6 k €-116,3 k €-337,4 k €
Net result-127,8 k €-80,9 k €9,9 k €
Balance sheet
Equity437,8 k €-55,9 k €24,9 k €
Total assets619,6 k €143,8 k €272,8 k €
Cash530 k €71,6 k €51,3 k €
Debts34,1 k €199,8 k €247,9 k €

Valuation

Indicative valuation

As an indication, this company is worth

between 250 k€ and 500 k€
See the valuation

Board of directors

Source · NBB, accounts to 31/12/2025

5 active · 3 ended

Active mandates

Sofie Pattyn

Director · since 26 juin 2025

Active
Yvan Sergeant

Director · since 26 juin 2025

Active
6K venture capital

Director · since 02 juin 2025 · 0809.505.580

Represented by Cédric Szpirer

Active
Jakub Swiercz

Director · since 02 juin 2025

Active
SCIENSATION

Director · since 02 juin 2025 · 0799.470.733

Represented by Frédéric Sallmann

Active

Ended mandates

SCIENSATION

Director · since 20 novembre 2023 · until 01 juin 2029 · 0799.470.733

Represented by Frederic Sallmann

Ended
SCIENSATION

Director · since 20 novembre 2023 · 0799.470.733

Represented by Frédéric Sallmann

Ended
Jakub Swiercz

Director · since 27 octobre 2022

Ended

Other companies at this address

Rue Clément Ader 10 6041 Charleroi
CompanyCBE no.
2 Bridge WL● Active
1003.906.745
3D Fibroscreen● Active
1022.772.354
AdipoPharma Belgique● Active
1008.146.338
ATRYON BELGIUM● Active
0751.698.530
Brussels South Charleroi BioPark Dev● Active
0479.250.670
ConvEyXo● Active
0725.874.259
CONVEYXO GROUP● Active
1016.957.797
ELKEDONIA BELGIUM● Active
1021.635.177
ENDO TOOLS THERAPEUTICS● Active
0807.570.233
Enodia Therapeutics Belgium● Active
1039.324.811
EU BIOTECH CAMPUS● Active
0776.668.706
Exo-Harvest● Active
0803.425.264
Hemastatx● Active
1019.406.058
Immunofusion● Active
0804.563.629
ImmunXperts● Active
0552.755.587
INCHINN THERAPEUTICS● Active
0799.914.755
INSTAR BELGIQUE● Active
1039.395.085
KOKUMA● Active
0799.078.377
LYS MEDICAL● Active
0688.626.061
MILEUTIS● Active
1011.400.984

Full financial information

Source · NBB
202520242023
Type of accountMicro modelMicro modelMicro model
Start of the financial year01/01/202501/01/202427/10/2022
Closing of the financial year31/12/202531/12/202431/12/2023
Length of the financial year12 months12 months15 months
Filing date28/07/202620/08/202506/12/2024
General meeting30/06/202602/06/202502/12/2024
Currency of the financial yearEUREUREUR
NBB quality labelSatisfying controlsSatisfying controlsSatisfying controls

Financial ratios

Source · NBB

Looking for more information about this company?

Try for 7 days

Annual accounts filings

Source · NBB, 4 filings
ModelClosingGeneral meetingFiledLanguageDocument
Micro model31/12/202530/06/202628/07/2026FrenchPDF
Micro model31/12/202402/06/202520/08/2025FrenchPDF
Micro model31/12/202302/12/202406/12/2024FrenchPDF
Micro model31/12/202305/08/202426/08/2024DutchPDF

Indicative valuation

Order of magnitude

As an indication, this company is worth

between 250 k€ and 500 k€

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan
Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Board of directors

Source · NBB, accounts to 31/12/2025

5 active · 3 ended

Active mandates

Sofie Pattyn

Director · since 26 juin 2025

Active
Yvan Sergeant

Director · since 26 juin 2025

Active
6K venture capital

Director · since 02 juin 2025 · 0809.505.580

Represented by Cédric Szpirer

Active
Jakub Swiercz

Director · since 02 juin 2025

Active
SCIENSATION

Director · since 02 juin 2025 · 0799.470.733

Represented by Frédéric Sallmann

Active

Ended mandates

SCIENSATION

Director · since 20 novembre 2023 · until 01 juin 2029 · 0799.470.733

Represented by Frederic Sallmann

Ended
SCIENSATION

Director · since 20 novembre 2023 · 0799.470.733

Represented by Frédéric Sallmann

Ended
Jakub Swiercz

Director · since 27 octobre 2022

Ended

Ownership and network

Looking for more information about this company?

Try for 7 days

Belgian Official Gazette publications

Source · Belgian Official Gazette
  • Mandates27/02/2026
    DEMISSIONS, NOMINATIONS
    PDF
  • Mandates15/09/2025
    DEMISSIONS, NOMINATIONS
    PDF
  • Mandates16/06/2025
    STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, …) - SIEGE SOCIAL - CAPITAL, ACTIONS - DEMISSIONS, NOMINATIONS
    PDF
  • Mandates18/12/2023
    DEMISSIONS, NOMINATIONS
    PDF
  • Other31/10/2022
    RUBRIQUE CONSTITUTION (NOUVELLE PERSONNE MORALE, OUVERTURE SUCCURSALE, ETC...)
    PDF

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

  1. 2025
    Annual accounts 2025-127,8 k €↓
  2. 2024
    Annual accounts 2024-80,9 k €↓
  3. 2023
    Annual accounts 20239,9 k €
  4. 27/10/2022
    IncorporationPrivate limited company